BLUEJAY DIAGNOSTICS O.N. Aktie

Bluejay Diagnostics has entered into binding agreements for a private placement expected to raise gross proceeds of $8.5 million and is selling 3,655,917 common shares or pre-funded warrants at $2.325 each. In addition, two warrant series (G and H) are being issued that could bring in a further approximately $15.1 million upon full cash exercise. Net proceeds are intended to finance FDA approval activities including clinical trials, R&D and working capital and are expected to extend the company’s cash runway into the first quarter of 2027. » More on de.investing.com

Bluejay Diagnostics is partnering with Argonaut Manufacturing Services to build U.S. manufacturing capacity for its Symphony platform for near-patient sepsis diagnostics and to reduce reliance on foreign production. The Symphony system, whose IL-6 test is said to deliver results in about 20 minutes, is still in clinical development and requires FDA approval before it can be commercialized. Bluejay has a market capitalization of around US$2.25 million, a current ratio of 2.81 and negative free cash flow; the stock has fallen 54% over six months despite recent gains. » More on de.investing.com

Bluejay Diagnostics released its quarterly results as of March 31, 2026. Earnings per share amounted to $1.95 versus -$13.480 in the same quarter last year. » More on finanzen.net